SRR934982
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.453
- COAGULATION+0.438
- INFLAMMATORY_RESPONSE+0.336
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.324
- PANCREAS_BETA_CELLS+0.322
- BILE_ACID_METABOLISM+0.300
- APICAL_SURFACE+0.288
- ANGIOGENESIS+0.287
- TNFA_SIGNALING_VIA_NFKB+0.259
- ALLOGRAFT_REJECTION+0.257
Top 10 suppressed
- MYC_TARGETS_V1-0.568
- DNA_REPAIR-0.541
- MYC_TARGETS_V2-0.529
- OXIDATIVE_PHOSPHORYLATION-0.514
- UNFOLDED_PROTEIN_RESPONSE-0.497
- PROTEIN_SECRETION-0.462
- E2F_TARGETS-0.403
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.342
- MTORC1_SIGNALING-0.328
- PI3K_AKT_MTOR_SIGNALING-0.312
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1418604 | GTEX | — | 0.946 |
| 2 | MNG272 | — | — | 0.945 |
| 3 | SRR659472 | GTEX | — | 0.938 |
| 4 | SRR1366961 | GTEX | — | 0.937 |
| 5 | MNG1146 | — | — | 0.936 |
| 6 | SRR1335064 | GTEX | — | 0.934 |
| 7 | SRR1444559 | GTEX | — | 0.933 |
| 8 | SRR602839 | GTEX | — | 0.933 |
| 9 | SRR1320012 | GTEX | — | 0.931 |
| 10 | SRR1394343 | GTEX | — | 0.931 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.453 | Remibrutinib | — uncovered |
| COAGULATION | 0.438 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.336 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.324 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.322 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.288 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.287 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.259 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.257 | Idelalisib | — uncovered |
| MYOGENESIS | 0.237 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.223 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.217 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.212 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.203 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.198 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.195 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.141 | Idelalisib | — uncovered |
| APOPTOSIS | 0.066 | Idelalisib | — uncovered |